Contents

Biology and Pharmacology of Prostaglandins and Leukotrienes

Biosynthesis and Metabolism of Prostaglandins and Thromboxanes. Quantitative Determination in Biological Material

E. GRANSTRÖM 3

Discussion 10

Involvement of the Eicosanoids, Thromboxane A_2 and Leukotriene C_4 in Gastric Mucosal Damage

B. J. R. WHITTLE 12

Discussion 20

Microvascular Injury and the Role of Leukotrienes and Prostaglandins in Acute Mucosal Damage and Protection

G. PIHAN, and S. SZABO 23

Discussion 30

Inhibition of Prostaglandin Synthesis and Proliferation of the Gastric Mucosa

F. HALTER, A. BAUMGARTNER, and H. R. KOELZ 33

Discussion 41

Role of Prostaglandins in Intestinal Fluid Secretion

E. BEUBLER 44

Discussion 48

Novel Leukotriene D_4 Receptor Antagonists and 5-Lipoxygenase Inhibitors: Implications in Human Disease

A. W. FORD-HUTCHINSON 50

Discussion 55

Protective Effects on the Gastrointestinal Mucosa. New Aspects of the Last two Years

„Aggressive" and „Protective" Factors in the Pathogenesis of Peptic Ulcer Disease
W. D. W. REES, and C. J. SHORROCK 59
Discussion 65

Heartburn and Mucosal Barrier Weakness
J. J. BERNIER, and CH. FLORENT 66
Discussion 73

The Functional Role of Prostanoids in the Gastroduodenal Mucosa
G. BERTACCINI, and G. CORUZZI 75

Role of Leukotrienes in Gastric Mucosal Damage and Protection
B. M. PESKAR 81
Discussion 88

Effect of Prostaglandins on the Motility of the Digestive Tract
P. DEMOL 90
Discussion 105

Gastroduodenal Bicarbonate Secretion in Mucosal Protection
G. FLEMSTRÖM 107
Discussion 112

Prostaglandins and Cellular Restitution – Physiological and Pathological Implications
T. MIYAKE, M. MURAKAMI, and Y. KOBAYASHI 113
Discussion 117

Prostanoid Inhibition of Acid Secretion – Cellular Mechanisms in Canine Fundic Mucosa
A. H. SOLL 118
Discussion 127

The Protective Effects of Prostaglandins on the Gastric Microvasculature
P. E. O'BRIEN 129

Non-Steroidal Anti-Inflammatory Drugs and Peptic Ulcer
M. J. S. LANGMAN 140

Discussion 146

Mechanism of Injury to Gastric Mucosa by Non-Steroidal Anti-Inflammatory Drugs and the Protective Role of Prostaglandins
M. M. COHEN 148

Discussion 152

Can Nonantisecretory Doses of Prostaglandins Prevent Mucosal Damage in Non-Steroidal Anti-Inflammatory Drugs?
B. SIMON, H.-G. DAMMANN, and P. MÜLLER 153

Clinical Aspects of the Protective Effects of Prostaglandins on Non-Steroidal Anti-Inflammatory Drug-Associated Mucosal Injury
D. Y. GRAHAM 161

Discussion 168

Prostaglandins and Leukotrienes in Gastrointestinal Diseases – Present Clinical Role

Gastrointestinal Microbleeding and Ulcerogenic Drugs: Prevention by Co-Administration of Prostaglandins
C. JOHANSSON 173

Discussion 178

Exogenous Prostaglandins and Their Analogues in Gastric Ulcer Therapy
D. RACHMILEWITZ 182

Exogenous Prostaglandins and Their Analogues in Duodenal Ulcer Therapy
S. J. SONTAG 187

Discussion 198

Clinical Safety of Antiulcer Prostaglandins: An Overview
G. BIANCHI PORRO, and F. PARENTE 204

Discussion 210

Ulcer Healing Drugs and Endogenous Prostaglandins: Carbenoxolone, Antacids, Sucralfate, Bismuth, and H_2-Receptor Antagonists
H. RUPPIN 213
Discussion 223

Smoking and Ulcer Healing – Role for Prostaglandins?
E. J. S. BOYD, and K. G. WORMSLEY 227
Discussion 233

Ulcer Healing by Prostaglandins – Due to Decreased Acidity or Enhanced Mucosal Defense?
H. G. DAMMANN, T. A. WALTER, M. DREYER, B. DAU, P. MÜLLER, and B. SIMON 235
Discussion 245

Diarrheagenic Syndromes Sensitive to Prostaglandin Synthetase Inhibitors
J. RASK-MADSEN, E. BEUBLER, and K. BUKHAVE 246
Discussion 251

Colitis and Non-Steroidal Anti-Inflammatory Drugs
D. S. RAMPTON 254
Discussion 260

Therapeutic Role for Prostaglandins in Ulcerative Colitis?
D. RACHMILEWITZ 264
Discussion 268

Inflammatory Bowel Disease: Treatment Modalities and Mucosal Prostaglandin/Leukotriene Formation
P. SHARON 273
Discussion 281

Prostaglandins: Their Potential Therapeutic Value in the Upper Gastrointestinal Tract

The Natural History of Ulcer Disease and its Impact upon Therapeutic Options and Assessment of Drug Safety
M. J. S. LANGMAN 287

Benefits and Risks of Long-Term Medical Therapy with Histamine H_2-Receptor Antagonists in Ulcer Disease – A Physician's View
W. P. FRITSCH 291

Benefits and Risks of Long-Term Medical Therapy with Histamine H_2-Receptor Antagonists in Ulcer Disease: A Surgeon's View
V. SCHUMPELICK, G. ARLT, and G. WINKELTAU 296

The Surgical Approach to Ulcer Disease and its Complications – Has there been a Change in the Last Decade?
E. H. FARTHMANN, P. BUSS, ST. EGGSTEIN, and A. IMDAHL 302

The Efficacy of Prostaglandins in the Prevention of Stress Lesions in the Critically Ill Patient
R. SCHIESSEL 310

Discussion Following this Section
K. H. HOLTERMÜLLER 316

Subject Index 321

